Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing
Abstract Pharmacogenomics has the potential to inform drug dosing and selection, reduce adverse events, and improve medication efficacy; however, provider knowledge of pharmacogenomic testing varies across provider types and specialties. Given that many actionable pharmacogenomic genes are implicate...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13737 |
| _version_ | 1797244860662546432 |
|---|---|
| author | Callan Russell MaryAnn Campion Megan E. Grove Kelly Matsuda Teri E. Klein Euan Ashley Hetanshi Naik Matthew T. Wheeler Stuart A. Scott |
| author_facet | Callan Russell MaryAnn Campion Megan E. Grove Kelly Matsuda Teri E. Klein Euan Ashley Hetanshi Naik Matthew T. Wheeler Stuart A. Scott |
| author_sort | Callan Russell |
| collection | DOAJ |
| description | Abstract Pharmacogenomics has the potential to inform drug dosing and selection, reduce adverse events, and improve medication efficacy; however, provider knowledge of pharmacogenomic testing varies across provider types and specialties. Given that many actionable pharmacogenomic genes are implicated in cardiovascular medication response variability, this study aimed to evaluate cardiology providers' knowledge and attitudes on implementing clinical pharmacogenomic testing. Sixty‐one providers responded to an online survey, including pharmacists (46%), physicians (31%), genetic counselors (15%), and nurses (8%). Most respondents (94%) reported previous genetics education; however, only 52% felt their genetics education prepared them to order a clinical pharmacogenomic test. In addition, most respondents (66%) were familiar with pharmacogenomics, with genetic counselors being most likely to be familiar (p < 0.001). Only 15% of respondents had previously ordered a clinical pharmacogenomic test and a total of 36% indicated they are likely to order a pharmacogenomic test in the future; however, the vast majority of respondents (89%) were interested in pharmacogenomic testing being incorporated into diagnostic cardiovascular genetic tests. Moreover, 84% of providers preferred pharmacogenomic panel testing compared to 16% who preferred single gene testing. Half of the providers reported being comfortable discussing pharmacogenomic results with their patients, but the majority (60%) expressed discomfort with the logistics of test ordering. Reported barriers to implementation included uncertainty about the clinical utility and difficulty choosing an appropriate test. Taken together, cardiology providers have moderate familiarity with pharmacogenomics and limited experience with test ordering; however, they are interested in incorporating pharmacogenomics into diagnostic genetic tests and ordering pharmacogenomic panels. |
| first_indexed | 2024-04-24T19:17:43Z |
| format | Article |
| id | doaj.art-b38a2859a532460eb13ce046c3411157 |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-04-24T19:17:43Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-b38a2859a532460eb13ce046c34111572024-03-26T04:50:32ZengWileyClinical and Translational Science1752-80541752-80622024-03-01173n/an/a10.1111/cts.13737Knowledge and attitudes on implementing cardiovascular pharmacogenomic testingCallan Russell0MaryAnn Campion1Megan E. Grove2Kelly Matsuda3Teri E. Klein4Euan Ashley5Hetanshi Naik6Matthew T. Wheeler7Stuart A. Scott8Department of Genetics Stanford University Stanford California USADepartment of Genetics Stanford University Stanford California USAClinical Genomics Laboratory Stanford Medicine Palo Alto California USADivision of Pharmacy and Cardiology Stanford Health Care Palo Alto California USADepartment of Biomedical Data Science Stanford University Stanford California USAStanford Center for Inherited Cardiovascular Disease Stanford California USADepartment of Genetics Stanford University Stanford California USAStanford Center for Inherited Cardiovascular Disease Stanford California USAClinical Genomics Laboratory Stanford Medicine Palo Alto California USAAbstract Pharmacogenomics has the potential to inform drug dosing and selection, reduce adverse events, and improve medication efficacy; however, provider knowledge of pharmacogenomic testing varies across provider types and specialties. Given that many actionable pharmacogenomic genes are implicated in cardiovascular medication response variability, this study aimed to evaluate cardiology providers' knowledge and attitudes on implementing clinical pharmacogenomic testing. Sixty‐one providers responded to an online survey, including pharmacists (46%), physicians (31%), genetic counselors (15%), and nurses (8%). Most respondents (94%) reported previous genetics education; however, only 52% felt their genetics education prepared them to order a clinical pharmacogenomic test. In addition, most respondents (66%) were familiar with pharmacogenomics, with genetic counselors being most likely to be familiar (p < 0.001). Only 15% of respondents had previously ordered a clinical pharmacogenomic test and a total of 36% indicated they are likely to order a pharmacogenomic test in the future; however, the vast majority of respondents (89%) were interested in pharmacogenomic testing being incorporated into diagnostic cardiovascular genetic tests. Moreover, 84% of providers preferred pharmacogenomic panel testing compared to 16% who preferred single gene testing. Half of the providers reported being comfortable discussing pharmacogenomic results with their patients, but the majority (60%) expressed discomfort with the logistics of test ordering. Reported barriers to implementation included uncertainty about the clinical utility and difficulty choosing an appropriate test. Taken together, cardiology providers have moderate familiarity with pharmacogenomics and limited experience with test ordering; however, they are interested in incorporating pharmacogenomics into diagnostic genetic tests and ordering pharmacogenomic panels.https://doi.org/10.1111/cts.13737 |
| spellingShingle | Callan Russell MaryAnn Campion Megan E. Grove Kelly Matsuda Teri E. Klein Euan Ashley Hetanshi Naik Matthew T. Wheeler Stuart A. Scott Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing Clinical and Translational Science |
| title | Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing |
| title_full | Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing |
| title_fullStr | Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing |
| title_full_unstemmed | Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing |
| title_short | Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing |
| title_sort | knowledge and attitudes on implementing cardiovascular pharmacogenomic testing |
| url | https://doi.org/10.1111/cts.13737 |
| work_keys_str_mv | AT callanrussell knowledgeandattitudesonimplementingcardiovascularpharmacogenomictesting AT maryanncampion knowledgeandattitudesonimplementingcardiovascularpharmacogenomictesting AT meganegrove knowledgeandattitudesonimplementingcardiovascularpharmacogenomictesting AT kellymatsuda knowledgeandattitudesonimplementingcardiovascularpharmacogenomictesting AT terieklein knowledgeandattitudesonimplementingcardiovascularpharmacogenomictesting AT euanashley knowledgeandattitudesonimplementingcardiovascularpharmacogenomictesting AT hetanshinaik knowledgeandattitudesonimplementingcardiovascularpharmacogenomictesting AT matthewtwheeler knowledgeandattitudesonimplementingcardiovascularpharmacogenomictesting AT stuartascott knowledgeandattitudesonimplementingcardiovascularpharmacogenomictesting |